Preview

Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)

Advanced search
Open Access Open Access  Restricted Access Subscription or Fee Access

Hypertrophic cardiomyopathy caused by mutations in the PRKAG2 gene

https://doi.org/10.21508/1027-4065-2022-67-4-99-107

Abstract

Clinical observations of three cases of hypertrophic cardiomyopathy caused by mutations in the PRKAG2 gene with a debut in early childhood are presented. The  sisters whose father suffered from a severe form of  hypertrophic cardiomyopathy in  combination with Wolf—Parkinson—White syndrome and died at a young age from progressive heart failure are described. Early manifestation of  the disease is characteristic, while there was a combination of  ventricular preexitation syndrome and myocardial hypertrophy with rapid progression to extreme values. Hypertrophy was concentric symmetrical and biventricular. The main clinical symptom in  the first observation was frequent paroxysms of supraventricular tachycardia. New atrioventricular fenestrations were detected during dynamic observation, insufficient effectiveness of radiofrequency ablation, recurrence of supraventricular tachycardia, and a good response to propafenone were noted. The third clinical case is sporadic, a long-term follow-up for 15 years is presented and clearly reflects the progression of  the increase in myocardial hypertrophy and cardiac arrhythmias. The disease debuted from an early age in the form of hypertrophy in combination with severe bradycardia, which made drug therapy difficult. Due to the high risk of sudden cardiac death against the background of extreme myocardial hypertrophy, a cardioverter defibrillator was implanted. Signs of mitochondrial insufficiency according to skeletal muscle biopsy are described. 

About the Authors

I. V. Leontyeva
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation

Moscow



N. V. Shcherbakova
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation

Moscow



E. P. Kalachanova
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation

Moscow



S. A. Thermosesov
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation

Moscow



V. S. Sukhorukov
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation

Moscow



References

1. Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr В. et al. Mutations in the gamma (2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10: 1215- 1220. DOI: 10.1093/hmg/10.11.1215 (2001)

2. Lopez-Sainz A., Dominguez F., Lopes L.R., Ochoa J.P., Barriales-Villa R., Climent V., et. al. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis J Am Coll Cardiol 2020; 76(2): 186-197. DOI: 10.1016/j.jacc.2020.05.029

3. Porto A.G., Brun F., Severini G.M., Losurdo P., Fabris E., Taylor M.R.G. et al. Clinical Spectrum of PRKAG2 Syndrome. Circ Arrhythm Electrophysiol 2016; 9(1): e003121. DOI: 10.1161/CIRCEP.115.003121

4. Banankhah P., Fishbein G.A., Dota A., Ardehali R. Cardiac manifestations of PRKAG2 mutation. BMC Med Genet 2018; 19(1): 1. DOI: 10.1186/s12881-017-0512-6

5. Gollob M.H., Green M.S., Tang A.S., Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002;17: 229-234. DOI: 10.1097/00001573-200205000-00004

6. Thevenon J., Laurent G., Ader F., Laforêt P., Klug D., Duva Pentiah A. et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations. Europace 2017; 19: 651-659. DOI: 10.1093/europace/euw067

7. Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P., Perez-Atayde A.R. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362-372. DOI: 10.1056/NEJMoa033349

8. Fabris E., Brun F., Porto A.G., Losurdo P., Vitali Serdoz L., Zecchin M. et al. Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome. J Am Coll Cardiol 2013; 62(9): e17. DOI: 10.1016/j.jacc.2013.02.099

9. Aggarwal V., Dobrolet N., Fishberger S., Zablah J., Jayakar P., Ammous Z. PRKAG2 mutation: An easily missed cardiac specific non-lysosomal glycogenosis. Ann Pediatr Cardiol 2015; 8(2): 153-156. DOI: 10.4103/0974-2069.154149

10. van der Steld L.P., Campuzano O., Pérez-Serra A., Moura de Barros Zamorano M., Sousa Matos S., Brugada R. Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family. Am J Case Rep 2017; 18: 766-776. DOI: 10.12659/AJCR.904613

11. Hu J., Tang B., Wang J., Huang K., Wang Y., Lu S. et al. Familial Atrial Enlargement, Conduction Disorder and Symmetric Cardiac Hypertrophy Are Early Signs of PRKAG2 R302Q. Curr Med Sci 2020; 40(3): 486-492. DOI: 10.1007/s11596-020-2207-z


Review

For citations:


Leontyeva I.V., Shcherbakova N.V., Kalachanova E.P., Thermosesov S.A., Sukhorukov V.S. Hypertrophic cardiomyopathy caused by mutations in the PRKAG2 gene. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(4):99-107. (In Russ.) https://doi.org/10.21508/1027-4065-2022-67-4-99-107

Views: 404


ISSN 1027-4065 (Print)
ISSN 2500-2228 (Online)